GlassScriptPhysician profile
Jamie Kiehm
NPI 1508152810
$4,167.58
in general payments reported to CMS, 2019-2025
23 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $729 · 2021: $1,109 · 2022: $1,297 · 2023: $42.54 · 2024: $103 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,013.59 | 2019-2025 | |
| Glaxosmithkline, LLC. | $676.47 | 2019-2023 | Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $502.36 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $497.39 | 2019-2022 | |
| Optinose US, INC. | $333.70 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $226.14 | 2020-2022 | |
| Kaleo, INC. | $116.86 | 2019-2022 | |
| Alk-Abello, INC | $116.84 | 2019-2022 | |
| Acclarent, INC | $110.71 | 2019-2020 | |
| Biocryst US Sales Co., LLC | $102.04 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $82.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $63.68 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.43 | 2020-2021 | |
| Pfizer INC. | $48.37 | 2022 | |
| Jazz Pharmaceuticals INC. | $43.29 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $31.77 | 2021 | |
| Pharming Healthcare, INC. | $25.57 | 2020 | |
| Abbvie INC. | $25.38 | 2022 | |
| Amgen INC. | $23.91 | 2022 | |
| Circassia INC. | $19.73 | 2020 | |
| Stryker Corporation | $16.52 | 2022 | |
| Genentech USA, INC. | $15.33 | 2019 | |
| Smith+Nephew, INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Kiehm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.